Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease

被引：5

作者：

Papamichael, Konstantinos ^{[1
,7
]}

Vande Casteele, Niels ^{[2
]}

Abraham, Bincy P. ^{[3
]}

Ritter, Timothy ^{[4
]}

Jain, Anjali ^{[5
]}

Cheifetz, Adam S. ^{[6
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, Boston, MA USA

[2] Univ Calif San Diego, Dept Med, La Jolla, CA USA

[3] Houston Methodist Hosp, Dept Med, Houston, TX USA

[4] GI Alliance Res, Southlake, TX USA

[5] Prometheus Labs, San Diego, CA USA

[6] Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, Boston, MA USA

[7] Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, 330 Brookline Ave, Boston, MA 02215 USA

来源：

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 21卷 / 11期

关键词：

FAILURE;

D O I：

10.1016/j.cgh.2022.10.037

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：2978 / +

页数：5

共 50 条

[1] Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel Disease
Mahmoud, R.
Schultheiss, J.
Louwers, J.
van der Kaaij, M.
van Hellemondt, B.
Mahmmod, N.
van Boeckel, P.
Jharap, B.
Fidder, H.
Oldenburg, B.
JOURNAL OF CROHNS & COLITIS, 2021, 15 : S420 - S421
[2] REAL WORLD COMPARATIVE RISK OF SERIOUS INFECTION WITH ADALIMUMAB, VEDOLIZUMAB, AND INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Osterman, Mark T.
Long, Millie D.
Singh, Siddharth
Meyer, Nicole
Feng, Chaoling
Higgins, Kate
Hepp, Zsolt
Arikan, Dilek
Wang, Anthony
Feagan, Brian G.
GASTROENTEROLOGY, 2018, 154 (06) : S365 - S365
[3] RETROSPECTIVE STUDY OF DOSE ESCALATION WITH ADALIMUMAB, INFLIXIMAB, AND VEDOLIZUMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
Zhang, K. H.
Singh, H.
Twardowski, R.
Lu, C.
Wan, Y.
Null, K.
VALUE IN HEALTH, 2020, 23 : S143 - S143
[4] Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
Kamal, Mahmoud E.
Werida, Rehab H.
Radwan, Mahasen A.
Askar, Safaa R.
Omran, Gamal A.
El-Mohamdy, Marwa A.
Hagag, Radwa S.
INFLAMMOPHARMACOLOGY, 2024, 32 (05) : 3259 - 3269
[5] Pharmacokinetics and immunogenicity of Infliximab biosimilar in inflammatory bowel disease patients
Guardiola, J.
Rodriguez Alonso, L.
Padulles, N.
Santacana, E.
Serra, K.
Padulles, A.
Ruiz-Cerulla, A.
Gilabert, P.
Arajol, C.
Ibanez-Sanz, G.
Camps, B.
Colom, H.
Bas, J.
Morandeira, F.
Sanchez, E.
Orobitg, J.
Rodriguez Moranta, F.
JOURNAL OF CROHNS & COLITIS, 2019, 13 : S441 - S441
[6] Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease
Strik, A. S.
van den Brink, G. R.
Ponsioen, C.
Mathot, R.
Loewenberg, M.
D'Haens, G. R.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (08) : 1128 - 1134
[7] EFFECT OF VEDOLIZUMAB, INFLIXIMAB, AND ADALIMUMAB ON BILIARY INFLAMMATION IN INDIVIDUALS WITH PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE
Tse, Chung Sang
Raffals, Laura H.
Loftus, Edward V.
Gossard, Andrea
Lightner, Amy L.
GASTROENTEROLOGY, 2018, 154 (06) : S302 - S303
[8] Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease
Tse, C. S.
Loftus, E. V., Jr.
Raffals, L. E.
Gossard, A. A.
Lightner, A. L.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (02) : 190 - 195
[9] Adalimumab is effective in patients with inflammatory bowel disease in clinical remission on infliximab
Khan, M.
Heetun, Z.
Moloney, J.
Courtney, G.
Aftab, A. R.
IRISH JOURNAL OF MEDICAL SCIENCE, 2015, 184 : S73 - S74
[10] MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases
Shi, Yuan
He, Wei
Zhong, Ming
Yu, Minhao
GENOMICS, 2021, 113 (04) : 1988 - 1998

← 1 2 3 4 5 →